anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-26 and is reviewed periodically as new material appears.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The ice crystals that develop within frozen tofu (凍豆腐 dòngdòufu, 冰豆腐 bīngdòufu in Chinese, both meaning "frozen tofu") result in the formation of large cavities that appear to be layered. Frozen tofu takes on a yellowish hue in the freezing process. Frozen tofu originates in the Jiangnan region of China and is commonly made at home from soft tofu. It is also commercially sold as a specialty in Hong Kong, Taiwan, and other areas with Jiangnan emigrants. It is regularly paired with tatsoi as a winter dish. Frozen tofu is defrosted before serving and sometimes pressed to remove moisture prior to use. During freezing, the ice crystals puncture cell walls and facilitate the release of free and bound water and cause a decrease in total water content in tofu after freezing then thawing. The initial protein-water bonds are irreversibly replaced by protein-protein bonds, which are more elastic and cause a structural change to the gel network and lead to an increase in textural properties such as hardness, springiness, cohesiveness, and gumminess. In Japan, two kinds of freeze-dried tofu are produced. Those are usually rehydrated by being soaked in water prior to consumption. In their dehydrated state, they do not require refrigeration.
===== MeSH D08.811.399.894 – racemases and epimerases (EC 5.1) ===== MeSH D08.811.399.894.200 – amino acid isomerases MeSH D08.811.399.894.200.200 – alanine racemase MeSH D08.811.399.894.500 – carbohydrate epimerases MeSH D08.811.399.894.500.700 – UDP-glucose 4-epimerase
When asked at trial why she had not spoken against the ongoing physical, emotional, and sexual abuse she had endured for seven years before running away from home when she was aged 15, Anna Marie emphasised that, as a child and adolescent, she had not known any other normality, adding, "[My father and stepmother] were all I had." Fred's younger brother, John, hanged himself in the garage of his Gloucester home in November 1996. At the time of his suicide, he had been awaiting the jury verdict in his trial for the alleged multiple rapes of his niece, Anna Marie, and another underage girl at Cromwell Street in the 1970s. The Wests' son Stephen is also known to have made a suicide attempt by hanging in 2002. In 2004 he was jailed for nine months for having unlawful sex with a 14-year-old girl on multiple occasions. Another of the West children, Barry, took his own life via a suspected drug overdose in October 2020 at the age of 40. For several years prior to his death, he is known to have battled a drug addiction and psychiatric problems as a result of the abuse he had endured and witnessed, including the murder of his sister Heather, as a child. The Wests' house in Cromwell Street was demolished in October 1996, with every piece of debris destroyed to discourage potential souvenir hunters. It had been referred to in the press as the "House of Horrors." The site was later redeveloped into a public pathway. As of May 2026, Rose remains incarcerated at New Hall jail, in Wakefield, West Yorkshire, where she maintains her innocence.
Sources: en.wikipedia.org
== Clinical significance == Variations in the CRHR1 gene is associated with enhanced response to inhaled corticosteroid therapy in asthma. CRF1 triggers cells to release hormones that are linked to stress and anxiety [original reference missing]. Hence CRF1 receptor antagonists are being actively studied as possible treatments for depression and anxiety. Variations in CRHR1 are associated with persistent pulmonary hypertension of the newborn.
will be different for geometries other than the center-cracked infinite plate, as discussed in the article on the stress intensity factor. Consequently, it is necessary to introduce a dimensionless correction factor,
==== Combinations of medications ==== A 2018 research review (16 studies included) found there was very little evidence to support or refute that combinations of medications were more effective than single medications for reducing fibromyalgia pain.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.